The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies.
Chiao-En WuChan-Keng YangMeng-Ting PengPei-Wei HuangChing-Fu ChangKun-Yun YehChun-Bing ChenChih-Liang WangChao-Wei HsuI-Wen ChenCheng-Tao LinShir-Hwa UengGigin LinYu-Fen LinChi-Yuan ChengJohn Wen-Cheng ChangPublished in: BMC cancer (2020)
Melanoma patients undergoing anti-PD-1 monotherapy and experiencing mild-to-moderate irAEs (grade 1-2), particularly skin (vitiligo)/endocrine irAEs had favorable survival outcomes. Therefore, the association between irAEs and the clinical outcomes in melanoma patients undergoing anti-PD-1 ICIs may be severity and type dependent.